drugset / Trial / NCT03867799
iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, single centre open-label, phase II interventional clinical trial of combination immunotherapy with Nivolumab and Relatlimab in mCRC.
Timeline
- Start
- 2019-03-27
- Primary completion
- 2022-10-21
- Completion
- 2024-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | Relatlimab | Monoclonal antibody | 160 mg | Intravenous |